Biogaia AB

BIOG-B.ST · Health Technology · Biotechnology · SE

158 employees · biogaia.se

About

BioGaia AB generates revenue through its probiotic product segments, primarily featuring Limosilactobacillus reuteri strains. The Paediatrics segment sells drops, gut health tablets, oral rehydration solutions, and cultures for licensee products. The Adult Health segment offers gut health tablets, oral health lozenges, and cultures integrated into dairy products by licensees. The Other segment includes royalties from development projects and revenue from CapAble's packaging solutions. Products are marketed globally to consumers seeking health benefits from probiotics, with licensees distributing branded items under agreements. The company targets health-conscious consumers through direct sales and licensed partnerships. Paediatrics products focus on infant and child health, while Adult Health products address digestive and oral wellness. CapAble, a subsidiary, contributes through packaging solutions, and royalties from development projects provide additional income streams. All segments operate under BioGaia's brand, leveraging documented health benefits of their probiotic strains.

Annual results

Reported figures, SEK · revenue up 8.2% in 2025

YearRevenueNet incomeNet marginFree cash flow
20251.5B332M21.6%—
20241.4B351M24.7%—
20231.3B365M28.2%—
20221.1B373M33.8%—
2021785M196M25.0%—

Dividends per share

2026 4.00 SEK2025 6.90 SEK2024 6.90 SEK2023 2.90 SEK2022 2.98 SEK

BIOG-B.ST in MarketPulse

The live chart with RSI and moving averages, the price, news, signals and price alerts for Biogaia AB are inside MarketPulse — currently in private beta.

Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.

Biogaia AB (BIOG-B.ST) — company profile and financials · MarketPulse